The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells

International Journal of Oncology

Volumn 47, Issue 1, 2015, Pages 262-268

  Arun, Banu ^a   Akar, Ugur ^a   Gutierrez Barrera, Angelica M ^a   Hortobagyi, Gabriel N ^a   Ozpolat, Bulent ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allelic loss; Autophagy; AZD2281; BRCA mutation; Breast cancer; Mitophagy; PARP inhibitors; Therapy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INIPARIB; OLAPARIB; VELIPARIB; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ALLELE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MITOPHAGY; MUTANT; PRIORITY JOURNAL; RNA INTERFERENCE; TRIPLE NEGATIVE BREAST CANCER; WILD TYPE; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENETICS; MCF 7 CELL LINE; MUTATION; TUMOR CELL LINE;

AUTOPHAGY; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMANS; MCF-7 CELLS; MITOCHONDRIAL DEGRADATION; MUTATION; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 84931022504     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3003     Document Type: Article

References (30)

1. Baynes RD, Dansey RD, Klein J.L., Hamm C., Campbell M, Abella E and Peters WP: High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future? Semin Oncol 28: 377-388, 2001.
2. Parkin DM, Bray F, Ferlay J and Pisani R Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005
3. Collaborative Group on Hormonal Factors in Breast Cancer: Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58, 209 women with breast cancer and 101, 986 women without the disease. Lancet 358: 1389-1399, 2001.
4. Ripperger T, Gadzicki D, Meindl A and Schlegelberger B: Breast cancer susceptibility: Current knowledge and implications for genetic counselling. Eur J Hum Genet 17: 722-731, 2009
5. Elstrodt F, Hollestelle A, Nagel J.H., Gorin M., Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP and Schutte M: BRCAl mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 66: 41-45, 2006.
6. Birgisdottir V, Stefansson OA, Bodvarsdottir S.K., Hilmarsdottir H., Jonasson JG and Eyfjord JE Epigenetic silencing and deletion of the BRCAl gene in sporadic breast cancer. Breast Cancer Res 8: R38, 2006.
7. Wilson CA, Ramos L, Villasenor M.R., Anders KH, Press MF, Clarke K, Karlan B., Chen JJ, Scully R, Livingston D, et al.: Localization of human BRCAl and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21: 236-240, 1999
8. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L and Easton DF: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCAl and BRCA2. J Clin Oncol 20: 2310-2318, 2002.
9. Palacios J, Honrado E, Osorio A., Cazorla A, Sarrió D, Barroso A, Rodriguez S, Cigudosa JC, Diez O, Alonso C, et al.: Phenotypic characterization of BRCAl and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90: 5-14, 2005
10. Moynahan ME, Chiu JW, Koller BH and Jasin M: Brcal controls homology-directed DNA repair. Mol Cell 4: 511-518, 1999
11. Tutt A, Bertwistle D, Valentine J., Gabriel A, Swilt S, Ross G., Grillin C, Thacker J and Ashworth A: Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 20: 4704-4716, 2001.
12. Tutt A and Ashworth A: The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 8: 571-576, 2002.
13. Huen MS and Chen J: Assembly of checkpoint and repair machineries at DNA damage sites. Trends Biochem Sci 35: 101-108, 2010.
14. Ashworth A: A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26: 3785-3790, 2008.
15. Herceg Z and Wang ZQ: Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 477: 97-110, 2001.
16. Wiltshire TD, Lovejoy CA, Wang T, Xia F., O'Connor MJ and Cortez D: Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. J Biol Chem 285: 14565-14571, 2010.
17. Bryant HE, Schultz N, Thomas H.D., Parker KM, Flower D, Lopez E, Kyle S., Meuth M, Curtin NJ and Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917, 2005
18. Farmer H, McCabe N, Lord C.J., Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon K.J., Hickson I., Knights C, et al.: Targeting the DNA repair delect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921, 2005.
19. Fong PC, Boss DS, Yap T.A., Tutt A., Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H., Lau A, O'Connor MJ, et al.: Inhibition of poly(ADP-ribose) polymerase in tumors Irom BRCA mutation carriers. N Engl J Med 361: 123-134, 2009
20. Tutt A, Robson M, Garber J.E., Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B., Loman N, Schmutzler RK, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A prool-ol-concept trial. Lancet 376: 235-244, 2010.
21. Murai J, Huang SY, Das B.B., Renaud A., Zhang Y, Doroshow JH, Ji J, Takeda S and Pommier Y Differential trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72: 5588-5599, 2012.
22. Yang Z and Klionsky DJ: Mammalian autophagy: Core molecular machinery and signaling regulation. Curr Opin Cell Biol 22: 124-131, 2010.
23. Dalby KN, Tekedereli I, Lopez-Berestein G and Ozpolat B: Targeting the prodeath and prosurvival lunctions of autophagy as novel therapeutic strategies in cancer. Autophagy 6: 322-329, 2010.
24. Akar U, Ozpolat B, Mehta K., Fok J, Kondo Y and Lopez-Berestein G: Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res 5: 241-249, 2007
25. Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell 132: 27-42, 2008.
26. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, et al.: High sensitivity of BRCAl-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105: 17079-17084, 2008.
27. Carey L, Winer E, Viale G., Cameron D and Gianni L Triple-negative breast cancer: Disease entity or title of convenience? Nat Rev Clin Oncol 7: 683-692, 2010.
28. Ashrali G and Schwarz TL: The pathways of mitophagy lor quality control and clearance of mitochondria. Cell Death Differ 20: 31-42, 2013.
29. Akar U, Chaves-Reyez A, Barria M., Tari A, Sanguino A, Kondo Y., Kondo S, Arun B, Lopez-Berestein G and Ozpolat B: Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy 4: 669-679, 2008.
30. Tekedereli I, Alpay SN, Akar U, Yuca E., Ayugo-Rodriguez C, Han HD, Sood A.K., Lopez-Berestein G and Ozpolat B: Therapeutic silencing of Bcl-2 by systemically administered-siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancer. Mol Ther Nucleic Acids 2: e121, 2013.